Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5201814 | 0.98 | CA1 (0.48) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL26017636 | 0.96 | CA1 (0.50) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL23775491 | 0.92 | CA12 (0.47) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL11898564 | 0.85 | CA1 (0.55) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL23620887 | 0.85 | CA1 (0.55) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL7104102 | 0.83 | CA12 (0.53) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL26290521 | 0.82 | CA1 (0.46) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL5851951 | 0.82 | CA1 (0.57) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL1638599 | 0.82 | CYP1A2 (0.50) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL65107 | 0.82 | CA12 (0.61) | CA1CA2CA12CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030358-B2 | Methods and pharmaceutical compositions for decorporation of radioactive compounds | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030358-B2 | Methods and pharmaceutical compositions for decorporation of radioactive compounds | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090124692-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATION OF RADIOACTIVE COMPOUNDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2009-05-14 | — | — | US | disclosed |
| US-20090124692-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATION OF RADIOACTIVE COMPOUNDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2009-05-14 | — | — | US | disclosed |
| EP-0773950-B1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20030105286-A1 | Linked peptide nucleic acids | EGHOLM MICHAEL (US) | 2003-06-05 | — | — | US | disclosed |
| US-6441130-B1 | FORM TRIPLE STRANDED STRUCTURES WITH NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0773950-A4 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0773950-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105286-A1 | Linked peptide nucleic acids | RNGTT, NT5C3B, DPYD | CA1 3250/4885CA2 4089/4885CA12 3393/4885 |
| US-20090124692-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DECORPORATION OF RADIOACTIVE COMPOUNDS | PIGS, SLC10A1, TRHDE | CA1 300/4885CA2 1490/4885CA12 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.